AIDOT Co., Ltd. (CEO Jaehoon Jung), a medical AI solution specialist, announced that its urinary stone diagnostic AI solution, 'URO dot AI,' now enables highly accurate detection of urinary stones from CT scans without the need for contrast agents. URO dot AI, developed in collaboration with Hanyang University Hospital, Bundang Seoul National University Hospital, and Seoul National University Hospital, utilizes AI to analyze CT images in three dimensions to precisely determine the location and size of urinary stones. It can accurately identify stones as small as 0.7mm with a sensitivity of 97.89%. This recent advancement incorporates an algorithm that distinguishes whether or not a contrast agent is present, achieving an internal validation accuracy of 99.7%. According to AIDOT's AI research team, “CT scanning is the gold standard for urinary stone diagnosis. Sometimes, contrast agent is injected for better anatomical visualization or differentiation of hydronephrosis or other lesions. However, injection of contrast agents requires scans within a short time window and often increases diagnostic time and patient cost, by about 30-50% versus non-contrast scans.” The team added, “With this new upgrade, URO dot AI enables fast, accurate urinary stone diagnostics without contrast agents, increasing clinical efficiency and reducing patient medical expenses.” Meanwhile, URO dot AI, designated as an integrated innovative medical device, is awaiting ministry notification for non-reimbursed commercialization within May. The solution’s clinical effectiveness and technological excellence have been recognized, having been published in the international urology journal Urolithiasis. 

Korea Economic TV / 2025.04.30 / Deputy Director Yang Jae-jun